report adjust ep consensu
expect higher estim strong revenu better-
than-anticip adjust oper margin perform lower-than-
expect tax rate drove upsid rel adjust ep
million consensu expect million
forecast million adjust result
adopt account standard codif lower
report revenu adjust sg expens million
revenu growth would exclud acquisit
chang foreign currenc exchang rate syk sale improv
organ includ impact one less sell day year-over-year
quarter estim led organ
growth neurotechnolog spine versu forecast
organ growth medsurg equip versu estim contrast
orthoped organ growth consist forecast
strong perform trauma extrem orthoped product
help off-set modestli lower organ growth knee implant
organ hip implant organ model
adjust result adopt adjust
oper margin improv bp year-over-year
estim slightli higher compani annual target
bp adjust oper margin expans quarter benefit
transform growth program off-set dilut
impact novadaq entellu acquisit adjust oper margin
follow strong result across board rais guidanc
adjust ep compani revis
outlook assum organ growth previous
least bp adjust oper margin expans
expect adjust ep versu prior consensu
expect
rais adjust ep estim
total debt total asset
deliv anoth quarter significantli better-than-expect organ
growth upsid consensu adjust ep estim addit weak
year margin perform encourag improv
perform area increas confid compani reach
upper end adjust oper margin guidanc particularli
anniversari suppli headwind relat product hurrican maria
overal remain posit long-term outlook
maintain buy rate new price target
import pleas read disclosur disclaim page report
report adjust ep consensu expect higher
estim strong revenu better-than-anticip adjust oper margin perform lower-than-
expect tax rate drove upsid rel adjust ep forecast
report basi syk revenu increas year-over-year million
consensu expect million forecast million adjust result
adopt account standard codif lower report revenu adjust
sg expens million revenu growth would exclud acquisit
chang foreign currenc exchang rate syk sale improv organ includ impact
one less sell day year-over-year quarter estim addit acquisit
currenc ad adjust revenu growth respect
stryker adjust incom statement analysisnorthcoast research million except percentag per share sg interest incom incom margin incom compani report northcoast research estim factset result reflect adopt account standard codif lower report revenu adjust sg expens million
divis standpoint strong result syk medsurg equip neurotechnolog spine busi
drove upsid rel organ growth forecast
medsurg equip achiev organ growth forecast
quarter medic organ growth remain particularli strong despit sale headwind
product suppli issu led third straight quarter double-digit growth core medic product stretcher
hospit bed physio-control addit syk endoscopi busi also continu post robust result
low-teen organ exclud novadaq acquisit led demand high-definit camera
corporationtot compani organ growth analysi two fewer sale day year-over-year one extra sale day year-over-year one fewer sale day year-over-year compani report corpor organ growth analysiscategorynorthcoastreportedtot compani organ orthoped medsurg equip neurotechnolog spine compani report northcoast research estim
neurotechnolog spine product achiev organ growth
forecast similar recent quarter neurotechnolog sale except strong organ
exclud entellu acquisit led ischem stroke busi meaning contribut
hemorrhag stroke neuro power instrument cmf product categori well contrast syk spine
organ growth remain letharg organ reflect difficult market condit particularli
orthoped product syk sale increas organ in-lin estim
quarter trauma extrem organ growth better anticip led growth
addit sale compani orthoped product stronger anticip
organ mako unit sale reach contrast combin hip knee organ
growth forecast combin slightli weaker market growth initi
expect modestli lower market share gain anticip weigh result
stryker corporationmedsurg equip organ growth analysi two fewer sale day year-over-year one extra sale day year-over-year one fewer sale day year-over-yearsourc compani report corporationneurotechnolog spine organ growth analysissourc compani report two fewer sale day year-over-year one extra sale day year-over-year one fewer sale day
knee implant achiev organ growth appear well better market rate track
year-over-year modestli forecast quarter syk knee implant organ
growth organ continu benefit increas demand cementless triathlon tritanium
knee system addit mako system sale competit account increas surgeon train
mako total knee implant applic versu syk earn call total
case perform syk mako total knee roughli
hip implant achiev organ growth forecast modestli
ahead market rate similar knee hip organ growth stronger unit state organ
elect procedur delay januari unit kingdom due sever flu season weigh
intern perform overal encourag syk hip result particularli given focu key
differenti knee mako total knee applic cementless knee offer within orthoped divis
adjust result adopt adjust oper margin improv
bp year-over-year estim slightli higher compani annual
target bp adjust oper margin expans quarter benefit transform
growth program off-set dilut impact novadaq entellu acquisit led
bp reduct adjust sg expens percent sale expens also slightli lower
anticip like reflect time issu bp improv adjust gross margin slightli
lower model modestli higher price declin year-over-year versu year-
over-year declin weigh perform
follow strong result across board rais guidanc adjust ep
compani revis outlook assum organ growth previous
least bp adjust oper margin expans moreov rais adjust ep
estim larg reflect higher organ growth forecast
overal deliv anoth quarter significantli better-than-expect organ growth upsid
consensu adjust ep estim addit weak year margin perform
encourag improv perform area increas confid compani reach
upper end adjust oper margin guidanc particularli anniversari suppli headwind
relat product hurrican maria overal remain posit long-term outlook
maintain buy rate new price target
stryker corporationannu incom statement analysi adjust northcoast research million except percentag per share gross gross sg intang oper oper net interest incom incom tax incom extra incom extra extra net net wghd com share ep ep growth ep growth start exclud acquistion-rel intang amort expens adjust ep adopt account standard codif lower report revenu adjust sg expens million sourc compani report northcoast research estim disclosur
